Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > AS more and more vaccines are coming on to the mkt..it means

<< Previous

Bullboard Posts

Next >>

Post by luvhorseson Mar 04, 2021 10:08pm

145 Views

Post# 32725062

AS more and more vaccines are coming on to the mkt..it means

bad news for AGN!!! Too much delay has caused the urgency of AGN's stuff to be really really low....hence, no demands for them!

AGN has lost it's golden opportunity last May to give its shareholders some hope...now, getting back to .54 let alone .44 is going to be a far cry now!!

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects